MediPharm Labs to Manufacture CBD Gelcaps for U.S. Clinical Trial

New York City Icahn School of Medicine at Mount Sinai and Renowned Global Researcher Dr. Hurd, Select MediPharm Labs to Support 500 Patient Major Clinical Study and “CBD International Consortium” to Develop Treatment of Opioid Addiction

MediPharm Labs enters major U.S. led opioid clinical research trial to develop IP and exclusively manufacture CBD gelcaps

TORONTO, May 22, 2019 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce it has been selected by The Mount Sinai Hospital, New York City (“Mount Sinai”), to participate in a clinical trial dedicated to developing a non-addictive oral gelcap medication for the treatment of opioid use disorder through anti-anxiety intervention utilizing hemp-derived CBD combined with a proprietary formula (the “Formula”). This

... read more at: https://www.newcannabisventures.com/medipharm-labs-to-manufacture-cbd-gelcaps-for-u-s-clinical-trial/